Application No	Applicant(s)	
•		
	ADAMS ET AL. Art Unit	
LAdillilei	Art offic	
Mark Navarro	1645	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to the amendment filed 2/25/05.		
2. The allowed claim(s) is/are 1-5, 8-9, 11-12, 18, 26, 47-50 and 64-66, renumbered as claims 1-18, respectively.		
3. The drawings filed on are accepted by the Examiner.		
 4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☐ hereto or 2) ☐ to Paper No./Mail Date 		
Paper No./Mail Date <u>7</u> . Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
6. ☐ Interview Summary Paper No./Mail Dat 8), 7. ☑ Examiner's Amendr	te	
	ars on the cover sheet with the coordinates of the appropriate communication and MPEP 1308. 2/25/05. 2/2	

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with William Wood on June 7, 2005.

The application has been amended as follows:

SPECIFICATION

Applicants continuing data statement filed June 7, 1995 was updated as follows: After the phrase "February 24, 1995," the phrase –(now U.S. Patent Number 6,420,152), which in turn was a file wrapper continuation application of application Ser. No. 08/082,845, filed June 23, 1993, (now abandoned),—was inserted.

CLAIMS

Claim 18, lines 1-2. The phrase "at least a portion of the Streptococcus pyogenes DNase B DNA sequence of claim 1 fused with another gene, with the fusion" was deleted and the phrase –a *Streptococcus pyogenes* DNase B amino acid sequence selected from the group consisting of: (1) *Streptococcus pyogenes* DNase B as shown in Fig. 4 (SEQ ID NO: 9); and (2) a *Streptococcus pyogenes* DNase B variant

Application/Control Number: 08/482,785

Art Unit: 1645

comprising the amino acid sequence shown in Fig. 4 (SEQ ID NO: 9) and having a deletion, insertion or substitution of one or more amino acids shown in Fig. 4 (SEQ ID NO: 9), wherein the variant is capable of being recognized and bound by anti-Streptococcus pyogenes DNase B antibody, and wherein the Streptococcus pyogenes DNase B is fused with another gene, and-- was inserted.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mark Navarro whose telephone number is (571) 272-0861.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

M

Mark Navarro Primary Examiner June 7, 2005